ClinChoice Extends 13-Year Medidata Partnership with the Addition of Clinical Data Studio to Improve Data Management and Strengthen Clinical Trial Capabilities
18.12.2024 14:00:00 CET | Business Wire | Press release
Renewed agreement integrates Medidata Platform, eliminating complex study processes and accelerating research through AI, automation, and advanced analytics
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has renewed its long-standing enterprise partnership with ClinChoice, a global contract research organization (CRO). Under this new agreement, ClinChoice will utilize the Medidata Platform to streamline study data and supply management, boost trial efficiency, and accelerate growth as a full-service CRO in Asia, Europe, and North America. ClinChoice also plans to prioritize Clinical Data Studio accreditation, further enhancing its capabilities through a transformative AI-powered data quality management experience.
ClinChoice’s commitment in utilizing Medidata’s solution has spanned over a decade, facilitating secure connections among patients, sites, and sponsors within a unified cloud environment. As an early adopter, ClinChoice played a critical role during the pandemic by deploying Rave RTSM’s Direct-to-Patient model, which maintained patient access and optimized inventory across diverse regions and regulatory requirements. By integrating Medidata’s solutions, ClinChoice continues to strengthen its operational efficiency and position itself for growth in today’s increasingly complex clinical trial landscape.
“Since our first implementation of Medidata Rave EDC in 2011, our partnership with Medidata has supported our development, starting in the U.S., then China, and eventually to the wider global stage,” said Ling Zhen, Global Chairman and CEO of ClinChoice. “We are delighted to extend our work together to include Medidata’s Clinical Data Studio and other advanced technologies to further boost our expansion.”
“ClinChoice’s dedication to innovation and patient-centered approaches makes them an invaluable partner,” said Edwin Ng, senior vice president and general manager, APAC, Medidata. “With this renewed partnership, we look forward to empowering ClinChoice with Medidata’s advanced solutions to further streamline their trial operations, expand their global reach, and accelerate access to life-changing therapies for patients worldwide.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 350,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
About ClinChoice
ClinChoice is a leading global Contract Research Organization (CRO) dedicated to providing full-service and functional solutions across the entire development lifecycle for pharmaceutical, biotechnology, medical device, and consumer product companies locally and globally. Established in 1995, ClinChoice employs more than 4,000 dedicated professionals in 30 different countries across Asia, Europe and North America.
ClinChoice is your complete source for comprehensive biometrics solutions designed to ensure your clinical trial data is held to the highest quality standards. Over the years, we’ve built a reputation as a preferred partner for our clients around the world by providing superior solutions that reduce complexities and speed up time to market for your products. With ClinChoice, you get more than just data analysis – you get a real, deep understanding of the latest methodology in regulatory innovation and the science of clinical development.
Going forward, ClinChoice will continue to build a global clinical ecosystem with dedicated professionals worldwide.
For more information, please visit www.clinchoice.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218165054/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom